Safety and Efficacy of OBX-115 in Advanced Solid Tumors

Inclusion Criteria:

Participant must be 18 years of age or older at the time of signing the informed consent.
Participant has a histologically confirmed diagnosis of advanced/metastatic melanoma ore relapsed refractory metastatic non-small cell lung cancer (NSCLC).
Melanoma participant experienced documented radiographic disease progression after systemic therapy containing a programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) blocking antibody. If the tumor is BRAF V600 mutation-positive, the participant should also have received a BRAF inhibitor with or without a MEK inhibitor. Participants with non-small cell lung cancer should have relapsed or are refractory to approved systemic therapies (approved ICI-based regimen for all appropriate participants and/or an approved targeted therapy for known molecular abnormalities if applicable to their disease).
Participant is assessed as having at least one lesion (or aggregate lesions) suitable for OBX-115 generation.
After tumor tissue procurement, the participant will have at least one remaining measurable lesion, as defined by RECIST v1.1.
Participant has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and an estimated life expectancy of >6 months.
Participant has recovered from all prior anticancer treatment-related AEs to at least Grade 1 (per Common Terminology Criteria for Adverse Events [CTCAE]).
Participants must have completed post-operative recovery from any prior surgical procedures with wound healing and resolution of all surgical complications prior to planned tumor procurement surgery.
Both male and female (women of childbearing potential) participants agree to the follow protocol specified contraceptive and/or abstinence requirements.
Participant has protocol specified hematologic parameters for absolute neutrophil count (ANC) and platelet count.
Participant has adequate cardiac, liver, lung, and kidney organ function as specified in the protocol.

Exclusion Criteria:

Participant has melanoma of uveal origin.
Participant has a history of brain metastases or leptomeningeal disease.
Participant has an active medical illness(es) that, in the opinion of the Investigator, would pose increased risks for study participation.
Participants with non-small cell lung cancer with refractory and clinically significant pleural effusions.
Participant has any form of primary or acquired immunodeficiency.
Participant has a history of hypersensitivity to any component of the study intervention.
Participant had another primary malignancy within the previous 3 years (with protocol specified exceptions).
Participant has a history of allogeneic organ transplant, allogeneic cell therapy, or genetically engineered cell therapy. Prior unegineered TIL cell therapy is allowed.
Participant requires systemic steroid therapy >10 mg/day of prednisone or equivalent.
Participant received a live or attenuated vaccination within 28 days prior to the start of lymphodepletion (LD).
Participant has evidence of positive infectious disease screening and/or any active uncontrolled viral, bacterial, or fungal disease requiring ongoing systemic treatment or identified during screening.